Odyssey Therapeutics is a clinical-stage biotechnology company developing precision medicines for autoimmune and inflammatory diseases. Its pipeline combines small-molecule and protein therapeutics aimed at selective targets in inflammatory signaling pathways. Lead programs address areas of high unmet need in immunology, including inflammatory bowel disease, rather than commercial marketed products today.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 1.8 | — | -36.8 | — |
| Q1 2025 | 1.9 | — | -38.4 | — |
| Q2 2025 | 1 | — | -41.2 | — |
| Q1 2026 | 0 | -100% | -38.3 | — |
| Q2 2026 | 0 | -100% | -52.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Westrock Coffee Company (WEST), ArriVent BioPharma, Inc. (AVBP), South Plains Financial, Inc. (SPFI), Orrstown Financial Services, Inc. (ORRF), AdaptHealth Corp. (AHCO), Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESY)